These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 27008812)

  • 1. DEVELOPMENT OF OLANZAPINE LOADED PNA MICROGELS FOR DEPOT DRUG DELIVERY IN TREATMENT OF SCHIZOPHRENIA: IN VITRO AN IN VIVO RELEASE PROFILE.
    Pervaiz F; Ahmad M; Hussain T; Idrees A; Yaqoob A; Abbas K
    Acta Pol Pharm; 2016; 73(1):175-81. PubMed ID: 27008812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and in vivo evaluation of solid lipid nanoparticulate systems of Olanzapine for acute phase schizophrenia treatment: Investigations on antipsychotic potential and adverse effects.
    Joseph E; Reddi S; Rinwa V; Balwani G; Saha R
    Eur J Pharm Sci; 2017 Jun; 104():315-325. PubMed ID: 28408348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The dual temperature/pH-sensitive multiphase behavior of poly(N-isopropylacrylamide-co-acrylic acid) microgels for potential application in in situ gelling system.
    Xiong W; Gao X; Zhao Y; Xu H; Yang X
    Colloids Surf B Biointerfaces; 2011 May; 84(1):103-10. PubMed ID: 21227660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and Characterization of Olanzapine Loaded Poly(lactide-coglycolide) Microspheres for Depot Injection: In vitro and In vivo Release Profiles.
    Pervaiz F; Ahmad M; Li L; Murtaza G
    Curr Drug Deliv; 2019; 16(4):375-383. PubMed ID: 30588882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual-stimuli responsive injectable microgel/solid drug nanoparticle nanocomposites for release of poorly soluble drugs.
    Town AR; Giardiello M; Gurjar R; Siccardi M; Briggs ME; Akhtar R; McDonald TO
    Nanoscale; 2017 May; 9(19):6302-6314. PubMed ID: 28368063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Olanzapine pamoate for the treatment of schizophrenia.
    Naber D
    Expert Opin Pharmacother; 2011 Mar; 12(4):627-33. PubMed ID: 21254860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microsphere delivery of Risperidone as an alternative to combination therapy.
    D'Souza S; Faraj J; DeLuca P
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):631-9. PubMed ID: 23892159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidences of extrapyramidal symptoms in patients with schizophrenia after treatment with long-acting injection (depot) or oral formulations of olanzapine.
    Hill AL; Sun B; McDonnell DP
    Clin Schizophr Relat Psychoses; 2014 Jan; 7(4):216-22. PubMed ID: 23428782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and evaluation of olanzapine-loaded PLGA nanoparticles for nose-to-brain delivery: in vitro and in vivo studies.
    Seju U; Kumar A; Sawant KK
    Acta Biomater; 2011 Dec; 7(12):4169-76. PubMed ID: 21839863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sucrose acetate isobutyrate as an in situ forming system for sustained risperidone release.
    Lu Y; Yu Y; Tang X
    J Pharm Sci; 2007 Dec; 96(12):3252-62. PubMed ID: 17721936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug safety evaluation of olanzapine pamoate.
    Schöttle D; Kuhnigk O; Naber D
    Expert Opin Drug Saf; 2013 Nov; 12(6):897-903. PubMed ID: 24024627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parenteral thermo-sensitive organogel for schizophrenia therapy, in vitro and in vivo evaluation.
    Wang D; Zhao J; Liu X; Sun F; Zhou Y; Teng L; Li Y
    Eur J Pharm Sci; 2014 Aug; 60():40-8. PubMed ID: 24815944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism.
    McDonnell DP; Detke HC; Bergstrom RF; Kothare P; Johnson J; Stickelmeyer M; Sanchez-Felix MV; Sorsaburu S; Mitchell MI
    BMC Psychiatry; 2010 Jun; 10():45. PubMed ID: 20537130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Olanzapine depot formulation in rat: a step forward in modelling antipsychotic-induced metabolic adverse effects.
    Skrede S; Martins L; Berge RK; Steen VM; López M; Fernø J
    Int J Neuropsychopharmacol; 2014 Jan; 17(1):91-104. PubMed ID: 23919889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-acting injectable formulations of antipsychotic drugs for the treatment of schizophrenia.
    Park EJ; Amatya S; Kim MS; Park JH; Seol E; Lee H; Shin YH; Na DH
    Arch Pharm Res; 2013 Jun; 36(6):651-9. PubMed ID: 23543652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia.
    Kane JM; Detke HC; Naber D; Sethuraman G; Lin DY; Bergstrom RF; McDonnell D
    Am J Psychiatry; 2010 Feb; 167(2):181-9. PubMed ID: 20008947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DoE based Olanzapine loaded poly-caprolactone nanoparticles decreases extrapyramidal effects in rodent model.
    Joseph E; Reddi S; Rinwa V; Balwani G; Saha R
    Int J Pharm; 2018 Apr; 541(1-2):198-205. PubMed ID: 29474898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pluronic block copolymers and Pluronic poly(acrylic acid) microgels in oral delivery of megestrol acetate.
    Alakhov V; Pietrzynski G; Patel K; Kabanov A; Bromberg L; Hatton TA
    J Pharm Pharmacol; 2004 Oct; 56(10):1233-41. PubMed ID: 15482637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro transdermal and biological evaluation of ALA-loaded poly(N-isopropylacrylamide) and poly(N-isopropylacrylamide-co-acrylic acid) microgels for photodynamic therapy.
    Gómez C; Benito M; Katime I; Teijón JM; Blanco MD
    J Microencapsul; 2012; 29(7):626-35. PubMed ID: 22494064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of metabolic changes in patients with schizophrenia during randomized treatment with intramuscular olanzapine long-acting injection versus oral olanzapine.
    McDonnell DP; Kryzhanovskaya LA; Zhao F; Detke HC; Feldman PD
    Hum Psychopharmacol; 2011 Aug; 26(6):422-33. PubMed ID: 21823172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.